DNA tumoral circulante na detecção da doença residual molecular e na predição de recidiva tumoral: avanços recentes e perspectivas clínicas.

Introduction: liquid biopsy, through the analysis of circulating tumor DNA (ctDNA), has become established in precision oncology as a tool to detect molecular residual disease and predict recurrence in solid tumors. Objective: to review recent advances in the use of ctDNA during follow-up after curative-intent treatment, highlighting clinical applications, therapeutic implications and current limitations. Methods: narrative literature review with a structured search strategy in PubMed/MEDLINE, SciELO and Google Scholar, using DeCS and MeSH descriptors combined with Boolean operators, covering 2021 to 2026; after screening of titles, abstracts and full texts, nine studies made up the final sample. Results: ctDNA detection after curative treatment identifies high-risk patients before radiological progression, with the most consistent evidence in colorectal cancer and promising results in breast cancer, non-small cell lung cancer and melanoma. Tumor-informed and tumor-agnostic approaches support risk stratification and individualized therapeutic decisions, including escalation and de-escalation of adjuvant therapy. However, analytical and clinical challenges remain, such as false-positive results caused by clonal hematopoiesis, reduced sensitivity at certain anatomical sites, lack of standardized protocols and high cost. Conclusion: ctDNA is a promising biomarker for the early detection of molecular residual disease and recurrence prediction, supporting personalized cancer care; nevertheless, its broad clinical adoption depends on further prospective validation, methodological standardization and cost reduction.

Authors

Publication Details

Journal
Revista fisio&terapia.
Published
2026-11-16
DOI
https://doi.org/10.69849/jsx60n93
Primary Topic
Cancer Genomics and Diagnostics
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

DNA tumoral circulante na detecção da doença residual molecular e na predição de recidiva tumoral: avanços recentes e perspectivas clínicas.

Marcos Martins Silva, Rafael Ramos Teles, Patrícia Maia, Laysla Tamyres de Oliveira Borges et al.
6 links
Revista fisio&terapia.
Cancer Genomics and Diagnostics
article

DNA tumoral circulante na detecção da doença residual molecular e na predição de recidiva tumoral: avanços recentes e perspectivas clínicas.

Marcos Martins Silva, Rafael Ramos Teles, Patrícia Maia, Laysla Tamyres de Oliveira Borges, Paulo Jorge Oliveira, Natalia Maria Valeriano da Silva, Victor Buarque Ribeiro de Siqueira, Maria Clara Gomes Oliveira, Mariana Gaspar Côrte Real, João Eduardo Cordeiro Ferreira dos Santos
article en

Abstract

Introduction: liquid biopsy, through the analysis of circulating tumor DNA (ctDNA), has become established in precision oncology as a tool to detect molecular residual disease and predict recurrence in solid tumors. Objective: to review recent advances in the use of ctDNA during follow-up after curative-intent treatment, highlighting clinical applications, therapeutic implications and current limitations. Methods: narrative literature review with a structured search strategy in PubMed/MEDLINE, SciELO and Google Scholar, using DeCS and MeSH descriptors combined with Boolean operators, covering 2021 to 2026; after screening of titles, abstracts and full texts, nine studies made up the final sample. Results: ctDNA detection after curative treatment identifies high-risk patients before radiological progression, with the most consistent evidence in colorectal cancer and promising results in breast cancer, non-small cell lung cancer and melanoma. Tumor-informed and tumor-agnostic approaches support risk stratification and individualized therapeutic decisions, including escalation and de-escalation of adjuvant therapy. However, analytical and clinical challenges remain, such as false-positive results caused by clonal hematopoiesis, reduced sensitivity at certain anatomical sites, lack of standardized protocols and high cost. Conclusion: ctDNA is a promising biomarker for the early detection of molecular residual disease and recurrence prediction, supporting personalized cancer care; nevertheless, its broad clinical adoption depends on further prospective validation, methodological standardization and cost reduction.

Revista fisio&terapia.Vol. 30(164)
Good health and well-being
Cancer Genomics and Diagnostics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon